Cardiovascular consequences of gestational diabetes
Green JB
Circulation. 2021;143(10):988-990
Leggi
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Davies M, Færch L, Jeppesen OK, et al.
Lancet. 2021;S0140-6736(21)00213-0
Leggi
Gestational diabetes history and glucose tolerance after pregnancy associated with coronary artery calcium in women during midlife – The CARDIA Study
Gunderson EP, Sun B, Catov JM, et al.
Circulation. 2021;143(10):974-987
Leggi
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial
von Herrath M, Bain SC, Bode B, et al.
Lancet Diabetes Endocrinol. 2021;S2213-8587(21)00019-X
Leggi
A pragmatic, randomized clinical trial of gestational diabetes screening
Hillier TA, Pedula KL, Ogasawara KK, et al.
N Engl J Med. 2021;384(10):895-904
Leggi
Heterogeneous long-term trajectories of glycaemic control in type 1 diabetes
Miller RG, Orchard TJ, Onengut-Gumuscu S, et al.
Diabet Med. 2021;e14545
Leggi
Sodium glucose co-transporter-2 (SGLT2) inhibitors and the risk of diabetic ketoacidosis: an example of complementary evidence for rare adverse events
Alkabbani W, Pelletier R, Gamble JM
American Journal of Epidemiology. Pub. online 6 March 2021
Leggi
Cardiovascular, renal, and metabolic outcomes of dapagliflozin versus placebo in a primary cardiovascular prevention cohort: analyses from DECLARE-TIMI 58
Cahn A, Raz I, Leiter LA, et al.
Diabetes Care. 2021;dc202492
Leggi
Comparison of long-term outcomes after percutaneous coronary intervention in patients with insulin-treated vs. non-insulin treated diabetes mellitus
Biswas S, Dinh D, Andrianopoulos N, et al.
The American Journal of Cardiology. Published online , 2 March 2021
Leggi
Progress in diabetes prevention or epidemiology – or both, or neither?
Ali MK, Seiglie JA, Narayan KMV
Lancet Diabetes Endocrinol. 2021;S2213-8587(20)30433-2
Leggi